Acute decompensation of heart failure is one of the main causes of repeated hospitalizations and worse survival rate. Studies aimed at exploring new opportunities to improve clinical status and prognosis remain highly relevant. Early administration of the type 2 sodium-glucose cotransporter inhibitors (iNGLT-2), in particular dapagliflozin, looks promising.
No takes yet. Share an insight, caveat, or question.
Arabidze et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: